Millennium Pharmaceuticals Inc: Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2007-12-25

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Millennium Pharmaceuticals focuses on the development and commercialization of products for the treatment of oncology and inflammatory diseases. The company's lead product is Velcade, used in the treatment of multiple myeloma, and is also being developed for use in treating other cancers, including lymphoma and lung cancer.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    Millennium Pharmaceuticals is engaged in developing and commercializing drugs and potential drugs for oncology and inflammatory diseases. The company markets one product, namely Velcade, for the treatment of multiple myeloma. The company is also focusing on opportunities to use Velcade in treating other cancers, including lymphoma and lung cancer.

    The company's total revenues increased at a CAGR of 8% during 2002-2006, from $353 million to $487 million. This represents an absolute total growth of +$134 million for total revenues during the same period. It's major contributor to revenue growth during 2002-2006 was Velcade, whose sales increased at an absolute growth of +$220 million.

    Millennium Pharmaceuticals's biggest contributor to sales growth out to 2010 will be the sales of Velcade. Revenues from Velcade are expected to increase at a CAGR of 15%, from $220 million in 2006 to $380 million in 2010. This represents an absolute growth of +$160 million, which is approximately 96.3% of total forecast growth out to 2010.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: pharmaceuticals millennium millenium mln8237 structure revenue price 2002 mln8054 pharmaceutical

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.